2Chang TT, Liaw YF, Wu SS, et al. Long term entecavir therapy results in the reversal of fibrosis cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology, 2010, 521 886-893.
3European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of chronic hepatitis B. J Hepatol, 2009, 50: 227-242.
5Liu F, Wang L, Li XY. Poor durability of lamivudine effectiveness despite stringent cessation criteria: A prospective clinical study in hepatitis B e antigen-negative chronic hepatitis B patients. J Gastroenterol Hepatol, 2011, 26: 456- 460.
6Locarnini S. Primary resistance, multidrug resistance, and cross- resistance pathways in HBV as a consequence of treatment failure. Hepatol Int, 2008, 2: 147-151.
7Tenney DJ, Pokorowski KA, Rose RE, et al. Entecavir maintains a high genetic harrier to HBV resistance through 6 years in naive patients. Gastroenterology, 2009, 136(5, Suppl 1): 865A.
8Yokosuka O, Takaguehi K, Fujioka S, et al. Long-term use of entecavir in nucleoside-naive Japanese patients with chronic hepatitis B infection. J Hepatol, 2010, 52: 791-799.
9Snow-Lampart A, Chappell B, Curtis M, et al. No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfeeted with chronic hepatitis B virus. Hepatology, 2011, 53: 763-773.
10Dienstag JL. Hepatitis B virus infection. N Engl J Med, 2008,359: 1486-1500.
二级参考文献13
1Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. 42 Dongsi Xidajie,Beijing 100710,China.慢性乙型肝炎防治指南[J].中华肝脏病杂志,2005,13(12):881-891. 被引量：1931
6Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association.肝衰竭诊疗指南[J].中华肝脏病杂志,2006,14(9):643-646. 被引量：831
